glp-1 gastroparesis legal team in louisiana The RA Timeline: How Serious Side Effects Led to Multidistrict Litigation Louisiana Diabetes Drugs & Gastrointestinal

And Pep19, a novel oral peptide that acts as an inverse agonist of the cannabinoid type 1 receptor, showed a 17% visceral fat reduction at the 5mg dose in a 60-day pilot trial, with every subject in the treatment group losing visceral fat

However, these gastrointestinal effects also contribute to the medication's side effect profile, which patients and healthcare professionals must carefully consider and manage

It selectively depletes many SCFA-producing taxa and enriches Gram-negative Proteobacteria

This participant had a corresponding large reduction in their GAD-7 score of 10 points and a drop in HbA1c from 84 to 68 mmol/mol